$DHR · DANAHER CORP /DE/
Danaher reported Q3 2026 results with net earnings of $1.2 billion ($1.71 per diluted share, up 34.5% YoY), revenue of $6.6 billion (+8.5% YoY), and non-GAAP adjusted diluted EPS of $2.11 (+11.5% YoY). Non-GAAP core revenue excluding respiratory revenue grew 5.5%. The company raised full-year 2026 adjusted EPS guidance to $8.57–$8.62 from $8.45–$8.60 and guided Q4 core revenue ex-respiratory growth of 4.0%–5.0%.
- Q3 net earnings were $1.2 billion, or $1.71 per diluted share, up 34.5% year-over-year.
- Non-GAAP adjusted diluted EPS grew 11.5% to $2.11.
- Revenue increased 8.5% year-over-year to $6.6 billion.
- Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year.
- Full-year 2026 adjusted EPS guidance raised to $8.57–$8.62 from prior $8.45–$8.60.
Extended-hours trading shows DHR at $212.00, down 5.36% from the $224.01 regular-session close, despite an earnings beat and raised full-year guidance. The selloff suggests the market is reacting to something beyond the headline numbers — possibly the modest core revenue growth of 3.0% or the respiratory revenue headwind.
A 5.4% after-hours drop on a beat-and-raise quarter signals the market is pricing in concerns about core growth trajectory or Masimo integration costs that headline numbers mask.
Danaher's mid-single-digit core growth (ex-respiratory) and double-digit adjusted EPS expansion reflect the life sciences and diagnostics sector's ongoing normalization post-pandemic, with the Masimo acquisition contributing to top-line but also adding amortization burden.
Respiratory revenue is expected to be an approximately 150 basis point headwind in Q4 2026. Tariffs, Masimo acquisition integration risks, and currency fluctuations are cited as ongoing uncertainties.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.